sellWeak cluster of 510b5-1 plan
Alexandra Balcom sold $2.1M of NUVL
Chief Financial Officer at Nuvalent, Inc.. 20,729 shares at an average of $99.62, traded Nov 17, 2025, filed Nov 19, 2025.
Warning score
37Value
$2.1M
20,729 shares
Holdings after
61,734
-25% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$2.1M at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-288317, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | MOption exercise Class A Common Stock10b5-1 | +6,875 | $6.89 | $47k | 68,609 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Class A Common Stock10b5-1 | +13,125 | $72.35 | $950k | 81,734 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,609 | $93.80 | $339k | 78,125 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,266 | $95.12 | $311k | 74,859 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -4,496 | $100.58 | $452k | 70,363 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -3,194 | $102.13 | $326k | 67,169 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -5,055 | $103.27 | $522k | 62,114 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -380 | $103.68 | $39k | 61,734 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Class A Common Stock10b5-1 | +729 | $72.35 | $53k | 62,463 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -220 | $103.61 | $23k | 62,243 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -509 | $104.54 | $53k | 61,734 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,875 | $0.00 | $0 | 29,101 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,125 | $0.00 | $0 | 34,375 | Nov 19, 2025 |
| Nov 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -729 | $0.00 | $0 | 33,646 | Nov 19, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.